Normally when you put out a product, you want to take sales away from the competition, not from other products that you sell yourself. But that's exactly what Gilead Sciences (NAS: GILD) is doing, and Motley Fool health care analyst David Williamson thinks it's a great move. Watch the video to find out why.
While you can certainly make huge gains in biotech and pharmaceuticals with major players like Gilead, it is an area not without big risks. That is why we here at the Fool say that the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Gilead: Biotech's Smartest Cannibal originally appeared on Fool.com.
David Williamson owns shares of Johnson & Johnson. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.